bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 million

Reuters2026/08/07 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

bioAffinity Technologies posted Q2 revenue of USD 1.5 million, up 19% year over year; net loss narrowed to USD 3.4 million.
CyPath Lung test volume rose 216% from Q2 2025; physician offices and clinics ordering the test increased 122%.
First-half CyPath Lung testing revenue climbed 159% to about USD 835,000; 1,097 test reports were delivered.
Operating expenses increased to USD 4.8 million from USD 3.8 million, reflecting higher clinical development and SG&A spending.
Management flagged priorities for the second half: expanding physician adoption, lifting existing-customer utilization, entering new systems including oncology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260807553380) on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

bioAffinity Q2 FY26 net loss narrows to $3.4 million; revenue rises 19% to $1.5 million

You may also like

Crypto prices